Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

201972 citationsJournal Articlebronze Open Access

Authors

ClinicalTrials.gov identifier: NCT00950300.

Good health and well-being

Published in: JAMA Oncology

Volume 5, Issue 5, pp. e190339-e190339

Field-Weighted Citation Impact: 4.35